Norges Bank Macrogenics Inc Transaction History

Norges Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 07, 2021	SELL	$18.99 - $33.2 $967,692 - $1.69 Million	-50,958 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$19.41 - $26.0 $989,094 - $1.32 Million	50,958 New	50,958 $1.17 Million
Q4 2020 Feb 10, 2021	SELL	$19.41 - $26.0 $989,094 - $1.32 Million	-50,958 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$24.69 - $31.6 $1.26 Million - $1.61 Million	50,958 New	50,958 $1.28 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $195M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.